Phase 3 Pancreatitis Trial, Recruiting NCT06860984 Sponsor: Tanta University Condition: Pancreatitis
Back to Pancreatitis

Phase 3 Pancreatitis Trial, Recruiting

NCT06860984
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You must be older than 18 years old.
  • Both men and women can take part.
  • You must have a medical reason to have a procedure called ERCP (a procedure used to examine and treat problems in the bile ducts or pancreas) due to a suspected problem in those areas.
  • Your blood levels of two enzymes related to the pancreas (called amylase and lipase) must be in the normal range before the procedure.

Who may not be able to join:

  • People with diabetes that is not well controlled.
  • People who have a serious problem with blood clotting or bleeding.
  • People whose kidneys are not working well enough (based on specific blood test results — confirm with trial site).
  • People with serious heart disease.
  • People who have previously had certain procedures on their bile duct or pancreas, such as a cut, widening, or placement of a tube (stent) in either area.
  • People who are currently pregnant or breastfeeding.
  • People who were admitted to hospital because they already had pancreatitis (inflammation of the pancreas) before the procedure.
  • People who do not want to have the ERCP procedure.

⚠️ Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Tanta University
Registry
ClinicalTrials.gov
Start date
10 March 2025
Est. completion
20 June 2026

Where this trial is recruiting

🇪🇬 Egypt

Primary endpoints

The primary outcome that will be measured is the development of pancreatitis after the procedure

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov